Marché mondial du syndrome de Bardet-Biedl – Tendances et prévisions de l’industrie jusqu’en 2030

Analyse du marché et de la taille du syndrome de Biedl-Bardet

Le syndrome de Biedl-Bardet (SBB) est une maladie héréditaire qui affecte plusieurs systèmes de l'organisme. Il est traditionnellement défini par six caractéristiques. L'obésité peut être un problème pour les patients atteints du SBB, en particulier le dépôt de graisse autour de l'abdomen. Ils présentent également fréquemment des déficiences intellectuelles. Les reins, les yeux et la fonction vaginale sont fréquemment touchés. Les patients atteints du SBB peuvent également avoir un doigt supplémentaire sur la main. Même parmi les membres d'une même famille, le degré du SBB varie considérablement. 

Data Bridge Market Research analyse que le marché mondial du syndrome de Bardet-Biedl, qui était de 349,22 millions USD en 2022, devrait atteindre 528,29 millions USD d'ici 2030 et devrait connaître un TCAC de 5,9 % au cours de la période de prévision 2023 à 2030. Le segment des « tests génétiques » domine le marché en raison de la prévalence croissante des maladies chroniques. En plus des informations sur le marché telles que la valeur marchande, le taux de croissance, les segments de marché, la couverture géographique, les acteurs du marché et le scénario du marché, le rapport de marché organisé par l'équipe de Data Bridge Market Research comprend également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché du syndrome de Biedl-Bardet

Market Definition

Bardet-Biedl syndrome (BBS) is a rare hereditary multisystem condition characterized by a wide range of mild manifestations, including obesity, genitourinary, retinal dystrophy, polydactyly, and renal defects, learning difficulty, and hypogonadism. Treatment and multidisciplinary management are required. There is no targeted treatment available. The majority of manifestations are treated in the same way that the general public is (obesity, learning disability, kidney anomalies). Surgery is also recommended for the correction of genital anomalies and polydactyly.

Biedl-Bardet Syndrome Market Dynamics

Drivers

• Rising incidences of obesity

The surging incidences of obesity are a major factor driving the market's growth rate. Obesity is a prevalent component of Bardet-Biedl syndrome (BBS), thus it's especially crucial to address it. Only a few people with Bardet-Biedl syndrome (BBS) have undergone bariatric surgery with gastric banding or sleeve surgery. In those patients, surgery was linked to a 25 percent weight decrease that was maintained 12 months later. Long-term follow-up of these individuals is being done to investigate if bariatric surgery has a function in patients with Bardet-Biedl syndrome (BBS).

• Rising healthcare infrastructure

Enhanced healthcare infrastructure, including advanced medical equipment and facilities, can lead to improved diagnostic capabilities. This is crucial for rare diseases like Bardet-Biedl syndrome, which may require specialized testing and expertise for accurate diagnosis.

Opportunities

• Increasing number of research and development activities

Increasing research activities can lead to the discovery of new genetic markers and diagnostic tools for Bardet-Biedl syndrome. This can enhance the accuracy and efficiency of diagnosis. Enhanced research can facilitate the initiation of clinical trials for potential treatments or interventions. This provides patients with the opportunity to participate in experimental therapies.

• Increasing technological advancements

Technological advancements in genetic testing and sequencing have the potential to make the diagnosis of BBS faster, more accurate, and more accessible. Next-generation sequencing technologies can identify the specific genetic mutations associated with BBS. Advanced data analysis and bioinformatics tools can assist researchers and clinicians in identifying genetic variations and understanding the complex genetic underpinnings of BBS.

Restrains

• Strict regulations and guidelines

Regulations govern the conduct of clinical trials, including those related to rare diseases. Researchers and pharmaceutical companies conducting clinical trials for potential BBS treatments must adhere to ethical and safety standards set by regulatory agencies.

• High cost of treatment

Managing the complex medical needs associated with BBS can be costly, and the financial burden on patients and their families can be significant. Coping with the financial burden of high treatment costs, especially when combined with the emotional and psychological impact of living with a rare disease, can place additional stress on individuals and their families.

Challenges

• Diagnostic challenges

The diagnosis of BBS can be challenging due to its genetic complexity. Identifying the specific genetic mutations responsible for the condition may require specialized testing, and not all healthcare providers are familiar with the syndrome.

This Bardet-Biedl syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Bardet-Biedl syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In February 2022, Rhythm Pharmaceuticals had announced the United States Food and Drug Administration (FDA) extension of review period for IMCIVREE (setmelanotide) for patients suffering from Bardet-Biedl syndrome and Alström syndrome. In the United States, IMCIVREE is approved for the treatment of obesity in adults and children aged 6 and up who have a deficiency in proprotein convertase subtilisin/kexin type 1 (PCSK1), proopiomelanocortin (POMC), or leptin receptor (LEPR), as determined by genetic testing revealing pathogenic, likely pathogenic, or unknown significance variants in the PCSK1, POMC or LEPR genes 

Global Bardet-Biedl Syndrome Market Scope

The Bardet-Biedl syndrome market is segmented on the basis of inheritance, diagnosis, treatment, age of onset, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Inheritance

• Oligogenic
• Autosomal Recessive

Diagnosis

• Electroretinogram (ERG)
• Genetic Testing
• Others

Treatment

• Surgery
• Kidney Transplantation
• Medication
• Therapy
• Suppressor Therapy
• Gene Therapy
• Stem Cell Therapy
• Others

Age of Onset

• Childhood
• Neonatal
• Infancy
• Adolescent

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Bardet-Biedl Syndrome Market Regional Analysis/Insights

The Bardet-Biedl syndrome market is analyzed and market size insights and trends are provided by country, inheritance, diagnosis, treatment, age of onset, end-users and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina and rest of South America.

North America is expected to dominate the market and continue to show highest growth rate in the market due to the growing prevalence of Bardet-Biedl syndrome and rising healthcare expenditure will further propel the market’s growth rate in this region. In addition, growing presence of major key players will further propel the market’s growth rate in this region. Asia-Pacific is expected to grow during the forecast period of 2023-2030 due to the development of healthcare infrastructure in this region. Also, rising government initiatives will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.       

Healthcare Infrastructure growth Installed base and New Technology Penetration

Le marché du syndrome de Bardet-Biedl vous fournit également une analyse détaillée du marché pour chaque pays, la croissance des dépenses de santé pour les biens d'équipement, la base installée de différents types de produits pour le marché du syndrome de Bardet-Biedl, l'impact de la technologie à l'aide de courbes de vie et les changements dans les scénarios réglementaires des soins de santé et leur impact sur le marché du syndrome de Bardet-Biedl. Les données sont disponibles pour la période historique 2010-2020.

Analyse du paysage concurrentiel et des parts de marché du syndrome de Bardet-Biedl

Le paysage concurrentiel du marché du syndrome de Bardet-Biedl fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liées au marché du syndrome de Bardet-Biedl.

Certains des principaux acteurs opérant sur le marché du syndrome de Bardet-Biedl sont :

• F. Hoffmann-La Roche SA (Suisse)
• Mylan NV (États-Unis)
• Teva Pharmaceutical Industries Ltd. (Irlande)
• Sanofi (France)
• Pfizer Inc. (États-Unis)
• GlaxoSmithKline plc (Royaume-Uni)
• Novartis SA (Suisse)
• Merck & Co., Inc. (États-Unis)
• Allergan (Irlande)
• AstraZeneca (Royaume-Uni)
• Johnson & Johnson Private Limited (États-Unis)
• Hikma Pharmaceuticals PLC (Royaume-Uni)
• Société Bristol-Myers Squibb (États-Unis)
• Bayer AG (Allemagne)
• Boehringer Ingelheim International GmbH. (Allemagne)
• Dr. Reddy's Laboratories Ltd. (Inde)
• Gilead Sciences, Inc. (États-Unis)
• Amgen Inc. (États-Unis)
• Eli Lilly and Company (États-Unis)
• AbbVie Inc. (États-Unis)
• Lupin (Inde)
• Allergan (Irlande)

SKU-68498